Cargando…
Off‐label and unlicensed medicines to hospitalised children in Norway
OBJECTIVES: The aim of this study was to investigate the use of off‐label (OL) and unlicensed (UL) medicines to hospitalised children in Norway, to add to the current knowledge on use of medicines in this vulnerable patient group. METHODS: The study was performed as a cross‐sectional prospective stu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396330/ https://www.ncbi.nlm.nih.gov/pubmed/27334565 http://dx.doi.org/10.1111/jphp.12581 |
_version_ | 1783230047045287936 |
---|---|
author | Teigen, Arna Wang, Siri Truong, Bich Thuy Bjerknes, Kathrin |
author_facet | Teigen, Arna Wang, Siri Truong, Bich Thuy Bjerknes, Kathrin |
author_sort | Teigen, Arna |
collection | PubMed |
description | OBJECTIVES: The aim of this study was to investigate the use of off‐label (OL) and unlicensed (UL) medicines to hospitalised children in Norway, to add to the current knowledge on use of medicines in this vulnerable patient group. METHODS: The study was performed as a cross‐sectional prospective study. Medication was classified as on‐ or off‐label based on the comparison with the SmPC regarding age, indication, dosage, route of administration and handling of the product. UL products were classified as imported or pharmacy produced. KEY FINDINGS: More than 90% of children receiving medicines in our study were given OL or UL medicines. More patients received OL (83%) than UL (59%). Route of administration was the most frequently observed OL category. The vast majority of the OL prescriptions were for ‘off‐patent’ products. One‐third of products prescribed were UL. CONCLUSIONS: The study confirms that medicines to children in hospital to a significant degree are being used outside or without authorisation, in spite of recent paediatric regulatory initiatives. More data are still needed on efficacy and safety of medicines used in children, data to be incorporated in the SmPC. In addition, suitable formulations are needed to ensure optimal dosing and adherence without risky manipulations. |
format | Online Article Text |
id | pubmed-5396330 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-53963302017-04-25 Off‐label and unlicensed medicines to hospitalised children in Norway Teigen, Arna Wang, Siri Truong, Bich Thuy Bjerknes, Kathrin J Pharm Pharmacol Research Papers OBJECTIVES: The aim of this study was to investigate the use of off‐label (OL) and unlicensed (UL) medicines to hospitalised children in Norway, to add to the current knowledge on use of medicines in this vulnerable patient group. METHODS: The study was performed as a cross‐sectional prospective study. Medication was classified as on‐ or off‐label based on the comparison with the SmPC regarding age, indication, dosage, route of administration and handling of the product. UL products were classified as imported or pharmacy produced. KEY FINDINGS: More than 90% of children receiving medicines in our study were given OL or UL medicines. More patients received OL (83%) than UL (59%). Route of administration was the most frequently observed OL category. The vast majority of the OL prescriptions were for ‘off‐patent’ products. One‐third of products prescribed were UL. CONCLUSIONS: The study confirms that medicines to children in hospital to a significant degree are being used outside or without authorisation, in spite of recent paediatric regulatory initiatives. More data are still needed on efficacy and safety of medicines used in children, data to be incorporated in the SmPC. In addition, suitable formulations are needed to ensure optimal dosing and adherence without risky manipulations. John Wiley and Sons Inc. 2016-06-23 2017-04 /pmc/articles/PMC5396330/ /pubmed/27334565 http://dx.doi.org/10.1111/jphp.12581 Text en © 2016 The Authors. Journal of Pharmacy and Pharmacology published by John Wiley & Sons Ltd on behalf of Royal Pharmaceutical Society This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Papers Teigen, Arna Wang, Siri Truong, Bich Thuy Bjerknes, Kathrin Off‐label and unlicensed medicines to hospitalised children in Norway |
title | Off‐label and unlicensed medicines to hospitalised children in Norway |
title_full | Off‐label and unlicensed medicines to hospitalised children in Norway |
title_fullStr | Off‐label and unlicensed medicines to hospitalised children in Norway |
title_full_unstemmed | Off‐label and unlicensed medicines to hospitalised children in Norway |
title_short | Off‐label and unlicensed medicines to hospitalised children in Norway |
title_sort | off‐label and unlicensed medicines to hospitalised children in norway |
topic | Research Papers |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5396330/ https://www.ncbi.nlm.nih.gov/pubmed/27334565 http://dx.doi.org/10.1111/jphp.12581 |
work_keys_str_mv | AT teigenarna offlabelandunlicensedmedicinestohospitalisedchildreninnorway AT wangsiri offlabelandunlicensedmedicinestohospitalisedchildreninnorway AT truongbichthuy offlabelandunlicensedmedicinestohospitalisedchildreninnorway AT bjerkneskathrin offlabelandunlicensedmedicinestohospitalisedchildreninnorway |